AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Late-summer 2026 hotel scorecard for Hilton, Marriott and Hyatt
Travel · Hotels · 22 August 2026

Late-summer 2026 hotel scorecard: Hilton, Marriott and Hyatt

Summer demand has stayed resilient, but the sector’s most important signal is not occupancy alone. For asset-light hotel groups, the handoff to fall is about RevPAR quality, fee growth, conversion openings and whether record pipelines become revenue-producing rooms on schedule.

Research cutoff: 22 August 2026 · Tickers: $HLT · $MAR · $H
Timing matters. Q2 includes April through June, not the full July–August peak. The article uses reported Q2 results plus management’s latest full-year and Q3 guidance. Any view on late summer, fall or early 2027 is explicitly presented as an inference or company outlook.

The sector verdict in 60 seconds

Demand measureRevPAR positiveComparable system-wide hotel RevPAR rose at all three groups in Q2.
Growth engineMore roomsPipelines remain large; openings and conversions turn contracts into recurring fees.
Main caveatRegional mixMiddle East disruption and softer all-inclusive demand show that global averages hide local weakness.

Bottom line: Hyatt posted the fastest Q2 hotel RevPAR growth and the fastest pipeline expansion, but its all-inclusive portfolio and back-half opening timetable deserve attention. Hilton delivered the highest reported net unit growth and a balanced RevPAR/EBITDA outlook. Marriott has the largest system and pipeline, with U.S. & Canada strength offsetting a Q2 international decline.

Reported scorecard

GroupQ2 operating evidenceDevelopment engine2026 company outlook
Hilton ($HLT)RevPAR +3.9%; adjusted EBITDA $1.054bn; adjusted EPS $2.29.541,300-room pipeline; 21,600 net room additions in Q2; net unit growth 6.1% YoY.RevPAR +3.0%–3.5%; adjusted EBITDA $4.04bn–$4.08bn.
Marriott ($MAR)Global RevPAR +3.4%; adjusted EBITDA $1.592bn; adjusted EPS $3.19.Record 629,000-room pipeline; 44% under construction; net rooms +4.5% YoY.Q3 RevPAR +3.5%–4.0%; FY26 +3.0%–3.5%.
Hyatt ($H)Hotel RevPAR +5.9%; gross fees +7.8% to $324m; adjusted EBITDA $297m.154,000-room executed pipeline, +10% YoY; TTM net rooms +3.9% or +4.4% excluding specified Playa removals.Hotel RevPAR +3.5%–4.5%; net rooms about +6%.

RevPAR figures are comparable and currency-neutral as defined by each company. Adjusted measures are non-GAAP and should be read with the issuers’ reconciliations.

What the summer handoff says about each stock

$HLT

Hilton: the cleanest unit-growth machine

  • System-wide comparable RevPAR rose 3.9% in Q2.
  • The pipeline reached 541,300 rooms after 42,900 approvals during the quarter.
  • Net unit growth was 6.1%, and the company launched Undergraduate by Hilton to target college and university markets.
Investor lens: Hilton’s late-summer case is less about a single demand spike and more about compounding fee streams through openings. The execution test is maintaining roughly mid-single-digit-to-high-single-digit unit momentum without weakening owner economics.
$MAR

Marriott: scale, loyalty and a record pipeline

  • U.S. & Canada RevPAR rose 5.0%, while international RevPAR slipped 0.5% amid Middle East disruption.
  • Franchise and base management fees rose 14% to $1.366bn.
  • Marriott Bonvoy exceeded 295 million members, while the development pipeline approached 629,000 rooms.
Investor lens: Scale and loyalty deepen the fee base, but global diversification can transmit regional shocks. The next season should show whether U.S. strength and conversions keep outweighing international volatility.
$H

Hyatt: premium demand leads, all-inclusive lags

  • Luxury and upper-upscale hotels drove Q2 RevPAR growth; leisure and group were strong.
  • All-inclusive Net Package RevPAR declined 1.2% as Mexico recovery remained slower than expected.
  • The executed rooms pipeline rose 10%, but some back-half openings may move into early 2027.
Investor lens: Hyatt has the best reported Q2 hotel RevPAR growth, but investors should not let the headline hide mixed portfolio signals and timing risk in planned openings.

How a hotel demand signal becomes shareholder value

1 · DemandOccupancy and room rates determine RevPAR.
2 · FeesRevPAR and system size drive base, franchise and incentive fees.
3 · OpeningsSigned pipeline must convert into operating rooms on time.
4 · CapitalAsset-light cash generation supports buybacks, dividends and brand investment.

The chain also reveals the risk: a huge pipeline is not current revenue. Construction, financing, conversion and opening dates decide when signed rooms begin paying fees. That is why Hyatt’s note about possible slippage into early 2027 is economically meaningful even with a larger pipeline.

What prepares the groups for the next season

ThemeLate-summer evidenceNext-season question
Rate versus occupancyAll three reported positive hotel RevPAR; Marriott highlighted continued ADR strength.Can rate hold when leisure mix normalizes after summer?
Business and groupHyatt’s group demand was strong; U.S. hotel performance was broadly supportive.Will fall conferences and corporate travel replace peak leisure nights?
ConversionsConversions represented more than one-third of Marriott’s signings and 40% of first-half openings.Can conversions deliver faster, lower-capital system growth?
Regional disruptionMiddle East conflict cut Marriott and Hyatt regional performance.Does weakness remain contained, or spread through international demand?
Opening calendarHilton and Marriott posted strong additions; Hyatt warned that some openings may shift to early 2027.Do year-end net room targets convert into actual fee revenue?

Fall/winter 2026–27 scenarios

Base case

RevPAR stays positive but normalizes after summer; group and corporate demand support urban hotels, while openings sustain fee growth. Full-year guidance remains achievable.

Upside case

ADR holds, international regions outside the Middle East remain firm and conversions open faster than planned. Fee growth outpaces RevPAR as the system expands.

Downside case

Leisure rates soften, regional disruptions persist and hotel financing delays openings. Pipeline headlines fail to convert into the expected net unit growth.

Investor checklist

  • Separate same-hotel RevPAR from growth created by adding rooms.
  • Track gross fees and incentive fees, not only reported revenue.
  • Compare pipeline growth with rooms under construction and actual openings.
  • Watch regional RevPAR and all-inclusive performance for hidden mix weakness.
  • Read buybacks alongside leverage and owner-funded development economics.

MerlinTrader bottom line

Best current unit-growth execution: Hilton. Deepest scale and pipeline: Marriott. Fastest Q2 RevPAR and pipeline growth, with more timing complexity: Hyatt. The common late-summer message is constructive, but the next decisive proof is whether booked rooms and signed projects become durable fee growth through fall and into 2027.

Continue with the Hilton Hub, Marriott Hub and Hyatt Hub, or return to the MerlinTrader Travel Pub.

Primary sources and freshness

  1. Hilton — Q2 2026 results, 28 July 2026.
  2. Marriott International — Q2 2026 results, 3 August 2026.
  3. Hyatt Hotels — Q2 2026 results, 30 July 2026.

Research cutoff: 22 August 2026. Outlook ranges are forward-looking and date-specific. RevPAR, adjusted EBITDA and other non-GAAP measures follow each issuer’s definitions.

Disclaimer. This article is for information and education only. It is not investment advice or a recommendation. Hotel results can change with macro demand, room rates, property financing, openings, geopolitics, weather, owner economics and currency. Review current filings and your own risk tolerance before investing.

Trending now

Merlintrader Biotech Radar, October 7, 2026: $ARWR, $ARVN, $LPCN, $MAIA and $RNXT; conceptual laboratory and molecular illustration.
Biotech Radar, October 7: regulatory progress, Parkinson’s data and oncology milestones
Illustration of the liver and metabolic research, with the original Merlintrader logo and ALT, VKTX, IVA and MDGL tickers.
MASH beyond weight loss: what $ALT, $VKTX, $IVA and $MDGL actually have to prove
Illustration of red blood cells and sickled cells, with the original Merlintrader logo and AGIO, CRSP, BEAM and NVO tickers.
Sickle cell: what progress means for $AGIO, $CRSP, $BEAM and $NVO
Illustration of muscle, DNA and a hand on a wheelchair control, with the original Merlintrader logo and CAPR, SRPT, RGNX and DYN tickers.
Duchenne: who remains outside the options at $CAPR, $SRPT, $RGNX and $DYN?